How far can we push the physical limits of storage?
The French deeptech Biomemory, born from the research of Sorbonne University and the CNRS, is taking a major step with the launch of DNA Shield.
Presented as its first commercial product based on its “molecular computing” platform, it is a managed offline data preservation service for critical information encoded in synthetic DNA.
DNA Shield targets information that an organization wants to preserve long-term integrity for: cryptographic keys, intellectual property, regulated records, or institutional archives. Data are first selected and encrypted by the client, then encoded into synthetic DNA stored offline, under managed custody.
Recovery is not designed as permanent or self-service access. Biomemory describes a controlled, triggered process that is activated when necessary. This is the case, notably, in the event of a cyberattack, a change in infrastructure, or the loss of availability of surrounding systems.
Biomemory presents the solution as a complement to a certified hardware security module, particularly for the continuity of safeguarding cryptographic keys.
Offline storage
Biomemory will open in the fourth quarter of 2026 an early-access program, reserved for organizations seeking to shield their most sensitive data
TechRadar Pro indicates that a pilot program is planned until mid-2027 before a wider availability of the service. The publication also mentions an Early Access subscription starting at €10,000 per month.
DNA Shield paves the way for “Molecular IT,” Biomemory’s roadmap, which foresees DNA data storage as of 2029, followed by molecular research and computing
« DNA Shield rests on the molecular platform we have spent years industrializing, but this is the first time we are asking a client to rely on it operationally, rather than merely as part of a research demonstration. Achieving this end-to-end—from encoding to secure retrieval—is what makes us the first company to bring molecular computing to market, » explains Vincent Franceschini, Biomemory’s Vice President of Product Management, while not naming the client’s identity.
Acquisition of Catalog Technologies assets
The launch follows two events that reshaped the company’s scope.
In March 2026, Biomemory acquired the assets of Catalog Technologies, a U.S.-based company specializing in DNA storage and computation. The deal allowed it to recover patents, equipment, and a presence in Boston, though financial terms were not disclosed.
In July 2026, Biomemory appointed Laurent Guengant as Chief Executive Officer. His background, including almost twenty years at Hitachi, is expected to facilitate moving from research to industrialization and commercialization.
DNA storage remains an emerging field, limited to small volumes of high-value data. Biomemory nonetheless demonstrates its potential with the Ministry of the Armed Forces, with which it is exploring sovereign, off-network protection solutions.
Illustration: © DR
